Harrow Salute del bilancio
Criteri Salute finanziaria verificati 3/6
Harrow ha un patrimonio netto totale di $52.1M e un debito totale di $243.2M, che porta il suo rapporto debito/patrimonio netto a 466.8%. Le sue attività totali e le sue passività totali sono rispettivamente $399.5M e $347.4M. L'EBIT di Harrow è $30.5M rendendo il suo rapporto di copertura degli interessi 1.3. Ha liquidità e investimenti a breve termine pari a $75.1M.
Informazioni chiave
466.84%
Rapporto debito/patrimonio netto
US$243.18m
Debito
| Indice di copertura degli interessi | 1.3x |
| Contanti | US$75.06m |
| Patrimonio netto | US$52.09m |
| Totale passività | US$347.39m |
| Totale attività | US$399.48m |
Aggiornamenti recenti sulla salute finanziaria
Recent updates
HROW: Ophthalmic Portfolio And Trials Will Support Long Term Earnings Reacceleration
The updated analyst price target for Harrow now sits at $59, reflecting a mix of modestly adjusted growth, margin and P/E assumptions as analysts recalibrate their models following Q4 results and revised product revenue guidance. Analyst Commentary Recent Street research on Harrow shows a cluster of price target revisions around the time of the Q4 report, with several bearish analysts trimming their models after updating revenue assumptions and aligning with management guidance.Harrow: Now Is The Buy Time
Apr 20
HROW: Future Upside Will Depend On Cataract Franchise Trial Execution
Harrow's updated analyst price target has edged lower by less than $1, reflecting analysts' refreshed revenue and margin assumptions following recent fourth quarter based model updates across the Street. Analyst Commentary Street research has recently focused on recalibrating price targets for Harrow after the latest fourth quarter update, with most firms fine-tuning models rather than changing their broader stance on the company.HROW: Ophthalmic Portfolio Expansion And Trials Will Support Long Term Earnings Power
Analysts have modestly reduced their average price targets on Harrow to a range of about $60 to $91, reflecting updated revenue estimates for products like Iheezo and Vevye and refreshed models following the latest Q4 report. Analyst Commentary Recent research indicates that while the overall stance on Harrow remains constructive, several Bearish analysts have trimmed their price targets and underlying revenue assumptions following the Q4 report.HROW: Ophthalmic Pipeline And New Trials Are Expected To Strengthen Long Term Earnings Power
Analysts have trimmed their consolidated Harrow price target by a few dollars to reflect updated revenue estimates and product forecasts, while still viewing current growth and leverage characteristics as broadly consistent with comparable companies in the sector. Analyst Commentary Recent Street updates around Harrow are mixed, with several bearish analysts trimming price targets after incorporating the latest Q4 information and revised product assumptions.HROW: Future Upside Will Rely On Cataract Franchise Execution
Analysts have nudged their price target for Harrow higher to reflect slightly stronger assumptions for revenue growth and profit margins, as well as a modestly lower future P/E. This results in a small upward adjustment in their implied valuation in dollar terms.HROW: Future Upside Will Depend On Market Share Execution And Margin Expansion
Analysts have trimmed their price target on Harrow to $90.32 from $91.76, citing updated assumptions around revenue growth, profit margins, and a slightly lower future P/E multiple. What's in the News Harrow reaffirmed its full-year 2025 revenue guidance, keeping the range at US$270 million to US$280 million (Corporate Guidance).HROW: Future Upside Will Depend On Coverage And Market Share Execution
Analysts have nudged their price targets on Harrow higher, with moves such as the shift to $66 at Ladenburg and $94 at Cantor Fitzgerald. These adjustments support a modest uptick in our fair value estimate to $91.76 as they incorporate updated Q3 results, Vevye revenue assumptions and refined profitability expectations.HROW: Future Upside Will Rely On Execution And Insurance Coverage
Narrative Update Analysts have nudged their targets higher on Harrow, with recent price objectives rising to $66 and $94. These changes reflect updated models after the latest quarterly results and revised Vevye revenue assumptions.HROW: Raised Outlook Will Rely On Execution And Insurance Coverage
Narrative Update on Harrow Analysts have lifted their consolidated price target on Harrow from about $76 to roughly $90, noting updated models after recent quarterly results and refined expectations for Vevye revenue and future P/E assumptions. Analyst Commentary Bullish analysts are resetting their expectations higher for Harrow, with recent research pointing to revised models after the latest quarterly update and a closer look at Vevye revenue assumptions and future P/E expectations.HROW: Expanded Ophthalmic Pipeline Is Expected To Drive Stronger Long Term Earnings Power
Analysts have raised our Harrow fair value estimate to $59 from $42, reflecting higher modeled revenue growth, improving margin expectations, and a wave of increased Street price targets following stronger quarterly results and an expanded product and biosimilar pipeline. Analyst Commentary Recent Street commentary on Harrow has been broadly constructive, with multiple firms lifting price targets in response to stronger quarterly results, expanding ophthalmic franchises, and a more visible biosimilar contribution.
HROW: Expanding Ophthalmic Portfolio Will Drive Long-Term Revenue Mix Diversification
Analysts have raised their blended price targets for Harrow into a higher range, highlighted by recent increases to $66, $70, $74, and $94 per share. They cite a stronger long-term revenue and margin outlook supported by ophthalmic biosimilars, Vevye ramp expectations, and a more visible commercial roadmap.HROW: Expanding Ophthalmic Pipeline Will Drive Revenue Upside Beyond 2026
Analysts have raised their price target for Harrow from $68.18 to $70.63. They cite sustained confidence in the company's revenue growth potential and the strength of its commercial roadmap, despite slight adjustments in growth projections and profit margins.HROW: Expanding Ophthalmic Pipeline Will Drive Strong Revenue Momentum Through 2027
Analysts have raised their price targets for Harrow. The most recent consensus lifts expectations by up to $4 per share, citing confidence in the company's expanding pipeline and commercial strategy to deliver sustainable revenue and margin growth.Analysts Boost Harrow Price Targets Amid Strong Growth Prospects and Pipeline Optimism
Analysts have raised their average price target for Harrow, citing increased confidence in the company's commercial execution and long-term revenue growth potential. Recent updates reflect new targets up to $74, compared to previous levels between $42 and $70.Rising Specialty Ophthalmics And Biosimilars Will Open New Markets
Harrow's analyst price target has increased from $61.98 to $68.18. Analysts point to a stronger revenue growth outlook and heightened optimism regarding the company's commercial execution and product pipeline.Harrow, Inc. (NASDAQ:HROW) Looks Just Right With A 27% Price Jump
Oct 03
Rising Specialty Ophthalmics And Biosimilars Will Open New Markets
Analysts have raised Harrow's price target to $61.98, reflecting optimism about upcoming biosimilar launches, a strengthening market position in eye care, and expectations for upside to current revenue guidance. Analyst Commentary Introduction of ophthalmic biosimilars Byooviz and Opuviz expected to materially contribute to revenue starting in 2026.VEVYE And TRIESENCE Programs Will Expand Prescription Access
Harrow is focusing on boosting sales and profitability through patient affordability programs, strategic supply chain improvements, and next-gen product developments.Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)
Mar 29Harrow: A Name I Am Accumulating
Mar 19Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025
Mar 01Shareholders Should Be Pleased With Harrow, Inc.'s (NASDAQ:HROW) Price
Feb 17Harrow: The Triesence Relaunch
Dec 14Harrow: Spotlight On IHEEZO
Nov 16Harrow's Focus - Reviving Old Drugs In A Crowded Market
Oct 02Harrow: 3 Business Models, One Mission
Sep 10Borrowing Cash To Burn It: The Curious Case Of Harrow
Aug 21Harrow: The Bull Thesis Is On Track, But Short-Term Challenges Loom
May 02Harrow's Drug Iheezo Is Off To A Great Start
Feb 19Harrow: Temporary Disruption In Stock Price Creates Excellent Opportunity
Jan 30Analisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( $211.8M ) di HROW superano le sue passività a breve termine ( $96.3M ).
Passività a lungo termine: Le attività a breve termine di HROW ( $211.8M ) non coprono le sue passività a lungo termine ( $251.1M ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: Il rapporto debito netto/patrimonio netto ( 322.8% ) di HROW è considerato alto.
Riduzione del debito: Il rapporto debito/patrimonio netto di HROW è aumentato da 60.7% a 466.8% negli ultimi 5 anni.
Bilancio
Analisi della pista di contanti
Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.
Pista di liquidità stabile: Sebbene non redditizia HROW ha una pista di cassa sufficiente per più di 3 anni se mantiene il suo attuale livello positivo di flusso di cassa libero.
Previsione Cash Runway: HROW non è redditizia ma ha una liquidità sufficiente per più di 3 anni, anche con un flusso di cassa libero positivo e in calo del 20.8 % all'anno.
Scoprire le aziende sane
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/03 09:54 |
| Prezzo dell'azione a fine giornata | 2026/05/01 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Harrow, Inc. è coperta da 10 analisti. 8 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Thomas Shrader | BTIG |
| Steven Seedhouse | Cantor Fitzgerald & Co. |